# ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Source: https://onco.cc/trials/nct04143607/  
OnCo record `nct04143607` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Limertinib run by Jiangsu Aosaikang Pharmaceutical Co., Ltd., active.

## Summary

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT04143607 by Jiangsu Aosaikang Pharmaceutical Co., Ltd., with 337 participants enrolled, started 2019-07-23. Conditions listed: Locally Advanced or Metastatic NSCLC. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04143607
- Phase: 3
- Setting: A Phase III,Double-Blind, Randomised Study to Assess the Efficacy and Safety of ASK120067 Versus Gefitinib as First-Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- Enrolled: 337

## Sources

- ClinicalTrials.gov NCT04143607: https://clinicaltrials.gov/study/NCT04143607

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Limertinib](https://onco.cc/drugs/limertinib/)
- companies: [Aosaikang Pharmaceutical](https://onco.cc/companies/aosaikang-pharmaceutical/)
- key papers: [Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial](https://onco.cc/key-papers/paper-nct04143607-lancet-respir-med-2025/)

---
JSON: https://onco.cc/api/v1/entities/nct04143607.json